Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kura Oncology, Inc.KURA · Entity 4871 | SVP, General Counsel | January 22, 2019 | January 24, 2019 |
| Turning Point Therapeutics, Inc.TPTX · Entity 124461 | EVP & General Counsel | February 09, 2022 | February 11, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kura Oncology, Inc.
Report date January 22, 2019 · Filed January 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $15.47 · Expires 2029-01-21 | Direct | 100,000 |
Reported balance
After 2019-01-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-22 · Grant · Acquired 100,000 · Balance 100,000 F1: This option vests in 48 equal monthly installments commencing on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in 48 equal monthly installments commencing on the grant date.
Turning Point Therapeutics, Inc.
Report date February 09, 2022 · Filed February 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,979 |
Ending reported balance
After 2022-02-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-02-09 · Sale · Disposed 669 · Balance 11,696 F1: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021. Row 2 · 2022-02-09 · Grant · Acquired 16,283 · Balance 27,979 F2: Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.68 · Expires 2032-02-08 | Direct | 58,600 |
Reported balance
After 2022-02-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-09 · Grant · Acquired 58,600 · Balance 58,600 F3: 1/48th of the shares vest monthly following February 9, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021.
F2: Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan.
F3: 1/48th of the shares vest monthly following February 9, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2022 Filed Feb 11, 2022 18:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 58,600 | $0.00 Strike: $37.68 | $0.00 |
DisclosureSEC source: 0001209191-22-008981 · doc4.xml · derivative · entry 3 North Annette · CIK 0001341011 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,600 Underlying: Common Stock · 58,600 shares Expires 2032-02-08 F3 · derivative.exercise_date: 1/48th of the shares vest monthly following February 9, 2022. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 18:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantCommon Stock | 16,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008981 · doc4.xml · nonDerivative · entry 2 North Annette · CIK 0001341011 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,979 F2 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 18:09 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 669 | $36.30 | $24,284.70 |
DisclosureSEC source: 0001209191-22-008981 · doc4.xml · nonDerivative · entry 1 North Annette · CIK 0001341011 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,696 F1 · kind: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 17:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054117 · doc4.xml · derivative · entry 3 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,609 Underlying: Common Stock · 10,000 shares Expires 2029-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F2 · derivative.exercise_date: One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 17:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 10,000 | $80.00 | $800,000.00 |
DisclosureSEC source: 0001209191-21-054117 · doc4.xml · nonDerivative · entry 2 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,365 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 17:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionCommon Stock | 10,000 | $17.00 | $170,000.00 |
DisclosureSEC source: 0001209191-21-054117 · doc4.xml · nonDerivative · entry 1 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 17:16 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040984 · doc4.xml · derivative · entry 5 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,609 Underlying: Common Stock · 15,000 shares Expires 2029-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F5 · derivative.exercise_date: One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 17:16 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 6,634 | $77.82 | $516,257.88 |
DisclosureSEC source: 0001209191-21-040984 · doc4.xml · nonDerivative · entry 4 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,365 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F4 · price: The weighted average sale price for the transaction reported was $77.82, and the range of prices were between $77.59 and $78.21. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 17:16 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,700 | $77.37 | $208,899.00 |
DisclosureSEC source: 0001209191-21-040984 · doc4.xml · nonDerivative · entry 3 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,999 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F3 · price: The weighted average sale price for the transaction reported was $77.37, and the range of prices were between $76.575 and $77.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 17:16 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 5,666 | $75.94 | $430,276.04 |
DisclosureSEC source: 0001209191-21-040984 · doc4.xml · nonDerivative · entry 2 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,699 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F2 · price: The weighted average sale price for the transaction reported was $75.94, and the range of prices were between $75.49 and $76.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 17:16 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionCommon Stock | 15,000 | $17.00 | $255,000.00 |
DisclosureSEC source: 0001209191-21-040984 · doc4.xml · nonDerivative · entry 1 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. Read SEC document |
| May 06, 2021 Filed May 7, 2021 16:37 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionStock Option (right to buy) · Derivative | 5,882 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030925 · doc4.xml · derivative · entry 2 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,609 Underlying: Common Stock · 5,882 shares Expires 2029-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested. Read SEC document |
| May 06, 2021 Filed May 7, 2021 16:37 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionCommon Stock | 5,882 | $17.00 | $99,994.00 |
DisclosureSEC source: 0001209191-21-030925 · doc4.xml · nonDerivative · entry 1 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 19:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-019268 · doc4.xml · derivative · entry 7 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,491 Underlying: Common Stock · 20,000 shares Expires 2029-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F6 · derivative.exercise_date: One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 19:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 700 | $111.69 | $78,183.00 |
DisclosureSEC source: 0001209191-21-019268 · doc4.xml · nonDerivative · entry 6 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,483 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F5 · price: The weighted average sale price for the transaction reported was $111.69, and the range of prices were between $111.52 and $111.89. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 19:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 4,571 | $110.77 | $506,329.67 |
DisclosureSEC source: 0001209191-21-019268 · doc4.xml · nonDerivative · entry 5 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,183 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F4 · price: The weighted average sale price for the transaction reported was $110.77, and the range of prices were between $110.48 and $111.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 19:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 9,419 | $109.89 | $1,035,053.91 |
DisclosureSEC source: 0001209191-21-019268 · doc4.xml · nonDerivative · entry 4 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,754 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F3 · price: The weighted average sale price for the transaction reported was $109.89, and the range of prices were between $109.47 and $110.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 19:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 4,810 | $109.09 | $524,722.90 |
DisclosureSEC source: 0001209191-21-019268 · doc4.xml · nonDerivative · entry 3 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,173 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F2 · price: The weighted average sale price for the transaction reported was $109.09, and the range of prices were between $108.46 and $109.41. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 19:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 500 | $103.30 | $51,650.00 |
DisclosureSEC source: 0001209191-21-019268 · doc4.xml · nonDerivative · entry 2 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,983 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 19:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionCommon Stock | 20,000 | $17.00 | $340,000.00 |
DisclosureSEC source: 0001209191-21-019268 · doc4.xml · nonDerivative · entry 1 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 18:01 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 29,175 | $0.00 Strike: $140.01 | $0.00 |
DisclosureSEC source: 0001209191-21-009375 · doc4.xml · derivative · entry 2 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,175 Underlying: Common Stock · 29,175 shares Expires 2031-02-07 F2 · derivative.exercise_date: 1/48th of the shares vest monthly following February 8, 2021. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 18:01 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantCommon Stock | 6,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009375 · doc4.xml · nonDerivative · entry 1 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,483 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan. Read SEC document |
| February 02, 2021 Filed Feb 2, 2021 21:50 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionStock Option (right to buy) · Derivative | 9,016 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007041 · doc4.xml · derivative · entry 14 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,491 Underlying: Common Stock · 9,016 shares Expires 2029-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F12 · derivative.exercise_date: One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested. Read SEC document |
| February 02, 2021 Filed Feb 2, 2021 21:50 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 604 | $131.89 | $79,661.56 |
DisclosureSEC source: 0001209191-21-007041 · doc4.xml · nonDerivative · entry 12 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F11 · price: The weighted average sale price for the transaction reported was $131.89, and the range of prices were between $131.52 and $132.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 02, 2021 Filed Feb 2, 2021 21:50 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,752 | $130.64 | $490,161.28 |
DisclosureSEC source: 0001209191-21-007041 · doc4.xml · nonDerivative · entry 11 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F10 · price: The weighted average sale price for the transaction reported was $130.64, and the range of prices were between $130.23 and $131.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 02, 2021 Filed Feb 2, 2021 21:50 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,860 | $129.75 | $371,085.00 |
DisclosureSEC source: 0001209191-21-007041 · doc4.xml · nonDerivative · entry 10 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,356 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F9 · price: The weighted average sale price for the transaction reported was $129.75, and the range of prices were between $129.22 and $130.21. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 02, 2021 Filed Feb 2, 2021 21:50 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 500 | $128.74 | $64,370.00 |
DisclosureSEC source: 0001209191-21-007041 · doc4.xml · nonDerivative · entry 9 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,216 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F8 · price: The weighted average sale price for the transaction reported was $128.74, and the range of prices were between $128.12 and $129.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 02, 2021 Filed Feb 2, 2021 21:50 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 900 | $127.83 | $115,047.00 |
DisclosureSEC source: 0001209191-21-007041 · doc4.xml · nonDerivative · entry 8 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,716 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F7 · price: The weighted average sale price for the transaction reported was $127.83, and the range of prices were between $127.72 and $127.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 02, 2021 Filed Feb 2, 2021 21:50 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 400 | $126.66 | $50,664.00 |
DisclosureSEC source: 0001209191-21-007041 · doc4.xml · nonDerivative · entry 7 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,616 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F6 · price: The weighted average sale price for the transaction reported was $126.66, and the range of prices were between $126.30 and $127.05. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 02, 2021 Filed Feb 2, 2021 21:50 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionCommon Stock | 9,016 | $17.00 | $153,272.00 |
DisclosureSEC source: 0001209191-21-007041 · doc4.xml · nonDerivative · entry 6 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 21:50 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionStock Option (right to buy) · Derivative | 15,984 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007041 · doc4.xml · derivative · entry 13 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,507 Underlying: Common Stock · 15,984 shares Expires 2029-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F12 · derivative.exercise_date: One-fourth of the option vested on April 15, 2020. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 21:50 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 500 | $125.38 | $62,690.00 |
DisclosureSEC source: 0001209191-21-007041 · doc4.xml · nonDerivative · entry 5 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F5 · price: The weighted average sale price for the transaction reported was $125.38, and the range of prices were between $125.05 and $126.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 21:50 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,313 | $124.41 | $412,170.33 |
DisclosureSEC source: 0001209191-21-007041 · doc4.xml · nonDerivative · entry 4 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F4 · price: The weighted average sale price for the transaction reported was $124.41, and the range of prices were between $124.02 and $124.89. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 21:50 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 10,541 | $123.49 | $1,301,708.09 |
DisclosureSEC source: 0001209191-21-007041 · doc4.xml · nonDerivative · entry 3 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,813 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F3 · price: The weighted average sale price for the transaction reported was $123.49, and the range of prices were between $123.01 and $124.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 21:50 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,630 | $122.58 | $199,805.40 |
DisclosureSEC source: 0001209191-21-007041 · doc4.xml · nonDerivative · entry 2 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,354 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F2 · price: The weighted average sale price for the transaction reported was $122.58, and the range of prices were between $121.95 and $122.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 21:50 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionCommon Stock | 15,984 | $17.00 | $271,728.00 |
DisclosureSEC source: 0001209191-21-007041 · doc4.xml · nonDerivative · entry 1 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 16:20 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 56,000 | $0.00 Strike: $63.33 | $0.00 |
DisclosureSEC source: 0001209191-20-002513 · doc4.xml · derivative · entry 1 North Annette · CIK 0001341011 · EVP, General Counsel & Secty. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2030-01-05 F1 · derivative.exercise_date: 1/48th of the shares will vest each month following January 6, 2020, so that all of the shares are vested four (4) years after January 6, 2020. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 21:11 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 100,000 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001209191-19-005134 · doc4.xml · derivative · entry 1 North Annette · CIK 0001341011 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-01-21 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:28 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 70,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-18-005608 · doc4.xml · derivative · entry 1 North Annette · CIK 0001341011 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 23, 2017 Filed Jan 25, 2017 22:32 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 72,000 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-17-005568 · doc4.xml · derivative · entry 1 North Annette · CIK 0001341011 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2027-01-22 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.